<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03896594</url>
  </required_header>
  <id_info>
    <org_study_id>HL237-102</org_study_id>
    <nct_id>NCT03896594</nct_id>
  </id_info>
  <brief_title>A Multiple Dose of HL237 in Healthy Male Subject</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo Controlled, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Oral Dose of HL237 in Healthy Male Subject</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HL237 is a new autoimmune therapeutic agent for rheumatoid arthritis, including the basic
      structure of biguanide in metformin, an existing diabetes drug.

      The immune modulating activity of HL237 was demonstrated in animal model. HL237 is a STAT3
      inhibitor and STAT3 is well known for an important regulator inhibiting Th17 cells and
      activating Treg cells.

      Therefore, when STAT3 activity is inhibited, it is expected to be able to treat autoimmune
      diseases such as rheumatoid arthritis.

      This is the first repeated administration clinical trial performed for the development of
      HL237 and is intended to evaluate the safety, tolerability and pharmacokinetics of each dose
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Doses are increased sequentially from low-capacity groups, and within six weeks after the
      last dose of the last subject in the ongoing dose phase, if available pharmacokinetic data
      are judged acceptable under review by investigators, sponsor and safety review committees,
      then proceed to the next dose stage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>14days after administration</time_frame>
    <description>maximum serum concentration after the drug has been administrated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve [AUC]</measure>
    <time_frame>14days after administration</time_frame>
    <description>AUC after the drug has been administrated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life [t1/2]</measure>
    <time_frame>14days after administration</time_frame>
    <description>Half life after the drug has been administrated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>14days after administration</time_frame>
    <description>Adverse Adverse Events, Serious Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>HL237 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL237 100mg 1 tablet twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HL237 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL237 100mg 2 tablets twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HL237 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HL237 400mg 1 tablet twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL237</intervention_name>
    <description>Experimental</description>
    <arm_group_label>HL237 200mg</arm_group_label>
    <arm_group_label>HL237 400mg</arm_group_label>
    <arm_group_label>HL237 800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>placebo with same properties except for active ingredient</description>
    <arm_group_label>HL237 200mg</arm_group_label>
    <arm_group_label>HL237 400mg</arm_group_label>
    <arm_group_label>HL237 800mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A healthy adult male aged 20 years or older and 45 years old at the time of the
             screening test

          -  Those who weigh more than 55kg but weigh less than Â± 20% of ideal body weight

          -  Proper contraception during the clinical trial period

          -  After hearing the detailed explanation of the clinical trial, those who decide to
             participate voluntarily and write agreement

        Exclusion Criteria:

          -  Clinically significant, a person with a history of neurological, psychiatric,
             malignant, cardiovascular, respiratory, kidney, endocrine, hematologic, digestive or
             central disease

          -  a person with a history of gastrointestinal disorders that may affect the absorption
             of pharmaceuticals for clinical trials (Crohn's disease, ulcers, etc.) or
             gastrointestinal surgery (except for simple cecal surgery or hernia surgery)

          -  a person with a history of hypersensitivity or clinically significant hypersensitivity
             to the clinical trial drug or additives

          -  a person judged to be inappropriate for the subject by health screening (history of
             disease, physical examination, vital signs, electrocardiogram, laboratory test, etc.)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seunghun Han</last_name>
    <phone>82-2-2258-7326</phone>
    <email>waystolove@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-gu</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seunghun Han</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>March 31, 2019</last_update_submitted>
  <last_update_submitted_qc>March 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

